Kimco Realty Corporation (HC) Common Stock vs TG Therapeutics Inc — how do they compare? Kimco Realty Corporation (HC) Common Stock trades at $22.17 (market cap $14.82B), while TG Therapeutics Inc trades at $55.11 (market cap $8.16B). The key difference: Kimco Realty Corporation (HC) Common Stock is the larger of the two by market cap, and Kimco Realty Corporation (HC) Common Stock pays a 5.07% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kimco Realty Corporation (HC) Common Stock for 1 Days and TG Therapeutics Inc for 16 Days on average.
| KIM | TGTX | |
|---|---|---|
Market Cap | $14.82B | $8.16B |
Volume | 5,158,462 | 1,735,121 |
Sector | Real Estate | Health |
52-Week High | $26.38 | $59.06 |
52-Week Low | $19.78 | $26.94 |
Typical Hold Time | 1 Days | 16 Days |
Enterprise Value | $22.98B | $8.37B |
Dividend Yield | 5.07% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Kimco Realty is a real estate investment trust that owns and operates open-air, grocery-anchored shopping centers and mixed-use properties in the United States.
Read more on KIM →TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →